EGFR and head and neck squamous cell carcinoma: In this regard, the observation that elevated circulating EGFR-specific T cells are found in HNSCC patients treated with the anti-EGFR antibodies Cetuximab and Nimotuzumab (155, 156), suggests that the presence of specific immune responses against ErbB receptors could be boosted by EGFR-targeted treatments.